| Title |
In-/off-label use of biologic therapy in systemic lupus erythematosus
|
|---|---|
| Published in |
BMC Medicine, February 2014
|
| DOI | 10.1186/1741-7015-12-30 |
| Pubmed ID | |
| Authors |
Mariele Gatto, Emese Kiss, Yaakov Naparstek, Andrea Doria |
| Abstract |
Current therapies for systemic lupus erythematosus (SLE) include corticosteroids as a persistent mainstay and traditional immunosuppressants which are given according to disease severity, organ involvement and patient status. No treatment entails certain efficacy devoid of mild-to-moderate adverse effects. Nowadays, novel therapies are being developed aiming to target specific molecules involved in SLE development and progression which show variable effectiveness and safety. Biologic agents considered for SLE comprise monoclonal antibodies (chimeric, humanized or fully human) as well as fusion molecules or antibody fragments mostly consisting of B cell-targeted therapies beside anti-cytokines as well as T cell-targeted therapies. Encouraging evidence on biologics is mostly provided by case series or uncontrolled studies; conversely, larger randomized controlled clinical trials have frequently missed their primary endpoints with the exception of BLISS-52 and BLISS-76 trials. Actually, apart from belimumab, biologics are employed in clinical practice as off-label treatments for lupus and results are often promising, depending on specific SLE features, dose regimens and individual responsiveness. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 25% |
| Chile | 1 | 13% |
| Bulgaria | 1 | 13% |
| Ecuador | 1 | 13% |
| United States | 1 | 13% |
| Unknown | 2 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 63% |
| Science communicators (journalists, bloggers, editors) | 2 | 25% |
| Practitioners (doctors, other healthcare professionals) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 24% |
| Other | 5 | 12% |
| Student > Bachelor | 5 | 12% |
| Student > Ph. D. Student | 4 | 10% |
| Professor | 3 | 7% |
| Other | 7 | 17% |
| Unknown | 7 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 34% |
| Chemistry | 3 | 7% |
| Business, Management and Accounting | 2 | 5% |
| Agricultural and Biological Sciences | 2 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Other | 6 | 15% |
| Unknown | 12 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 April 2016.
All research outputs
#6,055,347
of 22,745,803 outputs
Outputs from BMC Medicine
#2,319
of 3,413 outputs
Outputs of similar age
#58,236
of 223,273 outputs
Outputs of similar age from BMC Medicine
#41
of 57 outputs
Altmetric has tracked 22,745,803 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 3,413 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 43.5. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 223,273 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.